Description
Cell line name NCC-ESOS1-C1
Accession CVCL_YD21
Resource Identification Initiative To cite this cell line use: NCC-ESOS1-C1 (RRID:CVCL_YD21)
Comments Part of: NCC sarcoma cell line panel.
Population: Japanese.
Characteristics: Exhibits invasion capability (PubMed=31625124).
Doubling time: ~40 hours (PubMed=31625124); ~24 hours (DOI=10.2198/jelectroph.65.1).
Derived from site: Metastatic; Forearm, hypodermis; UBERON=UBERON_0002386+UBERON_0002072.
Sequence variations
Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=31625124).
Disease Extraskeletal osteosarcoma (NCIt: C8810)
Osteosarcoma (ORDO: Orphanet_668)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 58Y
Category Cancer cell line
STR profile
Source(s): PubMed=31625124
Markers:
Amelogenin | X |
CSF1PO | 12 |
D5S818 | 11,12,13 |
D7S820 | 10,12 |
D13S317 | 11,13 |
D16S539 | 9,10 |
D21S11 | 29,32 |
TH01 | 8,9 |
TPOX | 8 |
vWA | 14,18 |
Publications
PubMed=31625124; DOI=10.1007/s13577-019-00291-z
Kito F., Oyama R., Noguchi R., Hattori E., Sakumoto M., Endo M., Kobayashi E., Yoshida A., Kawai A., Kondo T.
Establishment and characterization of novel patient-derived extraskeletal osteosarcoma cell line NCC-ESOS1-C1.
Hum. Cell 33:283-290(2020)
DOI=10.2198/jelectroph.65.1
Noguchi R., Yoshimatsu Y., Ono T., Sei A., Kondo T.
Proteogenomic approach to drug targets in osteosarcomas with different original sites.
J. Electroph. 65:1-11(2021)
Cross-references
Cell line databases/resources cancercelllines; CVCL_YD21
Encyclopedic resources Wikidata; Q95992527
Reviews
There are no reviews yet.